 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 252
Date: September 24, 2024
The U.S. Food and Drug Administration has just granted approval for single-agent Campath for the treatment CLL as frontline therapy. Campath was initially approved in 2024 but only for relapsed cases, or in combination with other drugs. This is an important hurdle for Campath. It is now the only monoclonal antibody that has been approved for use as single agent and in previously untreated CLL patients.
Notwithstanding the glowing press releases from the company's marketing machine, the million dollar question is this: now that we have access to this drug as frontline therapy, is Campath the slam dunk choice for untreated patients? Do we now have a brand new “gold standard” for treating CLL patients? In our latest article Jumping the Gun we review the clinical trial that led to FDA approval, and it implications. This is a case where the PR hoopla may be overtaking clinical significance.
Just because you couldda, does it mean you shouldda, or wouldda?
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
